Adrian Newman-Tancredi
is also co-founder and
Chief Scientific Officer
of
Neurolixis Inc.

 

News

Adrian Newman-Tancredi will be chairing a session at an online neuroscience conference taking place from 17th to 19th June 2014. The webinar, organized by the online life-science...Read More
Rett syndrome is an orphan disorder that has devastating effects on the central nervous system. One of the most severe and life-threatening presentations of this syndrome is brainstem...Read More
Adrian Newman-Tancredi is co-PI of a research grant that has been awarded by International Rett Syndrome Foundation to Neurolixis Inc. Adrian is acting in his capacity as...Read More

NeuroAct Communication offers independent consulting in neuropharmacology and preclinical drug discovery to
bioscience companies, agencies and the investment community.